混合型肝细胞-胆管细胞癌:最新进展
混合型肝细胞-胆管细胞癌(cHCC-CCA)同时表现肝细胞与胆管分化,经典HCC危险因素也可使其易感。2019 WHO分类强调主要基于常规染色形态学诊断,免疫染色辅助亚型识别。分子证据支持其克隆性且与双表型组织学平行,预后一般差于HCC、类似iCCA,淋巴结清扫的切除是唯一治愈选择。
要点
- cHCC-CCA诊断主要基于常规染色形态学,免疫染色辅助亚型识别。
- 分子证据支持cHCC-CCA克隆性,遗传改变与HCC和/或iCCA经典改变平行。
- 淋巴结清扫的切除是唯一治愈选择,预后一般差于HCC、类似iCCA。
核心结论
- cHCC-CCA同时表现肝细胞与胆管分化,经典HCC危险因素也可使其易感。
- 2019 WHO分类强调诊断主要基于常规染色形态学,免疫染色辅助亚型识别。
- 分子证据支持cHCC-CCA克隆性,遗传改变与HCC和/或iCCA经典改变平行。
- 淋巴结清扫的切除是唯一治愈选择,预后一般差于HCC、类似iCCA。
研究设计与样本
- 综述,总结cHCC-CCA的病理定义演变、分子证据、诊断挑战与治疗现状。
主要发现
- 经典HCC危险因素似乎也使患者易感cHCC-CCA。
- 2019 WHO分类中「中间细胞癌」为特定亚型,「胆管细胞癌」现为iCCA亚型。
- cHCC-CCA的形态学诊断对放射科和病理科医生仍有挑战,尤其在活检标本上。
- cHCC-CCA的预后一般差于HCC,与iCCA相似。
- 淋巴结清扫的切除是cHCC-CCA患者唯一治愈选择。
关键数值与推荐
- 2019 WHO分类:cHCC-CCA诊断应主要基于常规染色形态学,免疫染色辅助亚型识别。
- 「中间细胞癌」被认定为特定亚型,「胆管细胞癌」现为iCCA亚型。
- 分子证据支持cHCC-CCA克隆性,遗传改变与HCC和/或iCCA经典改变平行。
- 淋巴结清扫的切除是唯一治愈选择,预后一般差于HCC、类似iCCA。
临床怎么用
- 诊断cHCC-CCA应主要基于常规染色形态学,免疫染色辅助亚型识别。
- 对cHCC-CCA患者,淋巴结清扫的切除是唯一治愈选择。
- cHCC-CCA的形态学诊断在活检标本上仍有挑战,需放射科和病理科医生注意。
局限性
- cHCC-CCA的形态学诊断对放射科和病理科医生仍有挑战,尤其在活检标本上。
- cHCC-CCA的细胞起源识别仍是活跃研究领域。
- 目前仍迫切需要为cHCC-CCA开发特异性治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumour that exhibits both hepatocytic and biliary differentiation. Classical risk factors for hepatocellular carcinoma (HCC) seem to also predispose patients to the development of cHCC-CCA. The pathological definition of cHCC-CCA has significantly evolved over time. The last 2019 WHO classification highlighted that the diagnosis of cHCC-CCA should be primarily based on morphology using routine stainings, with additional immunostaining used to refine the identification of subtypes. Among them, "intermediate cell carcinoma" is recognised as a specific subtype, while "cholangiolocellular carcinoma" is now considered a subtype of iCCA. Increasing molecular evidence supports the clonal nature of cHCC-CCA and parallels its biphenotypic histological appearance, with genetic alterations that are classically observed in HCC and/or iCCA. That said, the morphological diagnosis of cHCC-CCA is still challenging for radiologists and pathologists, especially on biopsy specimens. Identification of cHCC-CCA's cell of origin remains an area of active research. Its prognosis is generally worse than that of HCC, and similar to that of iCCA. Resection with lymph node dissection is unfortunately the only curative option for patients with cHCC-CCA. Thus, there remains an urgent need to develop specific therapeutic strategies for this unique clinical entity.
引用
- Beaufrère A, Calderaro J, Paradis V, et al. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol. 2021. PMID: 33545267. doi:10.1016/j.jhep.2021.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。